Beta estradiol and norepinephrine treatment of differentiated SH-SY5Y cells enhances tau phosphorylation at (Ser396) and (Ser262) via AMPK but not mTOR signaling pathway by Majd, Shohreh et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following article: 
Majd, S., Majd, Z., Koblar, S., & Power, J. (2018). Beta 
estradiol and norepinephrine treatment of differentiated 
SH-SY5Y cells enhances tau phosphorylation at (Ser 396 ) 
and (Ser 262 ) via AMPK but not mTOR signaling pathway. 
Molecular and Cellular Neuroscience, 88, 201–211. 
https://doi.org/10.1016/j.mcn.2018.02.004 
which has been published in final form at 
http://dx.doi.org/10.1016/j.mcn.2018.02.004
© 2018 Elsevier. This manuscript version is made 
available under the CC-BY-NC-ND 4.0 license:
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Accepted Manuscript
Beta estradiol and norepinephrine treatment of differentiated SH-
SY5Y cells enhances tau phosphorylation at (Ser396) and
(Ser262) via AMPK but not mTOR signaling pathway




To appear in: Molecular and Cellular Neuroscience
Received date: 3 July 2017
Revised date: 23 October 2017
Accepted date: 6 February 2018
Please cite this article as: Shohreh Majd, Zohreh Majd, Simon Koblar, John Power ,
Beta estradiol and norepinephrine treatment of differentiated SH-SY5Y cells enhances tau
phosphorylation at (Ser396) and (Ser262) via AMPK but not mTOR signaling pathway.
The address for the corresponding author was captured as affiliation for all authors. Please
check if appropriate. Ymcne(2017), https://doi.org/10.1016/j.mcn.2018.02.004
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may














Beta Estradiol and Norepinephrine Treatment of Differentiated SH-SY5Y 




) via AMPK 












a Neuronal Injury and Repair (NIR) Laboratory, Centre for Neuroscience, School of 
Medicine, Flinders University, Adelaide, Australia
 
b
 Psychosomatische Tagesklinic, Stadtturm, Passau, Bavaria, Germany  
c 





Corresponding (submitting) Author: Shohreh Majd 
Postal address of the submitting author: 
Neuronal injury and repair laboratory 
Flinders Medical Centre, Level 6, Rm 6E404 


























Hyperphosphorylation of tau is one of the main hallmarks for Alzheimer’s disease 
(AD) and many other tauopathies. Norepinephrine (NE), a stress-related hormone 17-
β-estradiol (E2) and thought to influence tau phosphorylation (p-tau) and AD 
pathology. The controversy around the impact of NE and E2 requires further 
clarification. Moreover, the combination effect of physiological and psychological 
stress and estrogen alteration during menopause, which affect p-tau, has not been 
addressed. Exposure to E2 is believed to reduce NE release, however, the link 
between these two hormones and AD at cellular level was also remained unknown. 
Here, we examined whether NE and E2 treatment of differentiated SH-SY5Y cells 
affected tau phosphorylation. The involvement of adenosine monophosphate kinase 
protein kinase (AMPK) and target of rapamycin (mTOR) as the possible mechanisms, 
underlying this effect was also investigated. Subsequent to SH-SY5Y differentiation 
to mature neurons, we treated the cells with NE, E2 and NE plus E2 in presence and 
absence of Compound C and Rapamycin. Cell viability was not affected by our 
treatment while our western blot and immunofluorescent findings showed that 














), while GSK-3β and PP2A activities were remained 





) due to NE+E2 treatment. Collectively, our results 
suggested that tau hyperphosphorylation due to exposure to NE/E2 was mediated by 
AMPK, the main energy regulator of cells during stress with no significant 
involvement of mTOR, GSK-3β and PP2A. 
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Hyperphosphoryalted tau (p-tau) is one of the two main signatures of Alzheimer’s disease 
(AD), the most common form of neurodegenerative disorders. AD prevalence in women is 
higher than in men (Vina and Lloret, 2010). Previously, it was thought that the natural decline 
of estrogen level during menopause increased the risk for AD (Manly et al., 2000), however 
numerous studies, failed to prove a significant effect of hormone therapy (HT) in reducing 
the risk of AD and tauopathy feature of it in human and animal trials (Imtiaz et al., 2017; 
Ohm et al., 2012). One essential but less studied factor in development of AD hallmarks in 
women, particularly during and after menopause is stress. The concurrent increase in 
norepinephrine (NE), along with the other stress-related hormones such as cortisol is usually 
anticipated to occur during menopause (Woods et al., 2009). It is believed that stress, both 
physiological and psychological, has a substantial role in generating tau phosphorylation, 
neuro-inflammation and altering blood brain barrier integrity (Feng et al., 2005; Mravec et 
al., 2014; Rissman et al., 2007). Interestingly, the ability of 17-β-estradiol (E2) to modulate 
NE functions has been reported previously (Herbison et al., 2000). It seems that E2-NE 
interaction enhances spatial memory during stress (Conrad et al., 2004) but impairs stress-
induced working memory (Shansky et al., 2004). A role for cAMP in memory impairment 
during stress has been suggested in E2-NE interaction scenario (Shansky et al., 2009), 
however the exact mechanism by which these hormones, develop p-tau is not fully 
understood.  
In brain tissue Adenosine Monophosphate Kinase Protein Kinase (AMPK) plays a key role in 
managing cellular homeostasis in response to a various range of environmental stress 
(Alexander and Walker, 2011). Apart from its role as the master of cell energy balance, 
AMPK was recently introduced as one of the main tau kinases, phosphorylating tau in many 








) (Domise et al., 2016; Majd et al., 
2017; Majd et al., 2016). Along with its direct effect on tau phosphorylation, AMPK inhibits 
target of rapamycin (mTOR) that acts as an intracellular nutrient sensor to control 
metabolism (Xu et al., 2012). Upregulation mTOR signaling pathway is thought to play an 
important role in major pathological processes of AD (Cai et al., 2015). Interestingly, NE 
enhances both AMPK and mTOR activation via increasing their phosphorylation, while E2 
activates AMPK activation (Chen et al., 2014; Hutchinson et al., 2005; Lipovka et al., 2015; 
Yin et al., 2003) with a very little known about their links to AD through activating 














Considering the role of stress in developing AD, the present study aims to investigate the 
effect of NE as one of the main elevated stress hormones during menopause, along with E2 
on tau phosphorylation, and to study the mechanism behind it. In order to examine this 





) in the presence of NE and E2. Here we showed that the co-treatment with both NE 




), with no impact on cell viability between 
different groups. We suggest that AMPK as the main metabolic pathway, activated under 
stress in neurons, builds the initial underlying mechanism for stress-induced tau 
phosphorylation, with no or less involvement of Glycogen Synthase Kinase-3β and Protein 










































Phosphorylated tau rabbit polyclonal antibody (Ser
396
; sc-101815), tau mouse monoclonal 
antibody (A-10; sc-390476), phosphorylated Glycogen Synthase Kinase-3β (p-GSK-3β) goat 
polyclonal antibody (Ser
9
; sc-11757), GSK-3β rabbit polyclonal antibody (H-76; sc-9166), 
phosphorylated Protein Phosphatase 2A (p-PP2A-Ca/b) mouse monoclonal antibody (F-8; sc-
271903), and PP2A-Aa goat polyclonal antibody (C-20; sc-6112) were purchased from Santa 




; MN1020B) was 
purchased from ThermoFisher Scientific. Mouse anti-microtubule associated protein (anti-
MAP2; ab11267) and β actin mouse monoclonal (ab6276) antibodies were purchased from 
Abcam, USA. The p-AMPK rabbit polyclonal (Thr
172
, #2531) and AMPK rabbit polyclonal 
antibody (#2532) were purchased from Cell Signalling Australia. Secondary antibodies were 
purchase from Jackson Immuno Research, USA (HRP donkey anti-mouse, anti-rabbit, anti-
goat, Alexa Fluor_488 Donkey anti-rabbit, anti-mouse, and CY3 Donkey anti-mouse).  
 
SH-SY5Y culture and differentiation 
Neuroblastoma SH-SY5Y cells (generously provided by Dr. Marie Louis Rogers, Motor 
Neuron Disease and Neurotrophic Research Laboratory, Flinders University) were cultured in 
T75 tissue culture flasks (Sarstedt, Australia) in complete Dulbecco’s Modified Eagle’s 
Medium and F12 (Sigma; DMEM/F12; 1:1) supplemented with 10 percent fetal bovine serum 
(FBS) (Sigma), 100 U/ml penicillin and 100 U/ml streptomycin (Sigma) in a humidified 
atmosphere of 95% air and 5% CO2 at 37°C. Cell culture medium were changed each 3 days 
and the cells were sub-cultured once they reached 90% confluence in 6 multi-well plates 
(Nunclon DELTA surface; NUNC A/S) for western blot analysis, or in 4 chamber tissue 
culture glass slides (BD Biosciences, USA) for immunofluorescent staining. The 
differentiation was started after 5-7 days when cells were about 70% confluence. To 
differentiate cells, the medium was replaced by complete but FBS free medium, contained all 
supplements plus 10 µM all trans-retinoic acid (RA, Sigma) (Lopes et al., 2010). The cells 
were kept in dark and humidified atmosphere of 95% air and 5% CO2 at 37°C. 
 














 All treatment were begun at day 7 of differentiation. Based on the experimental groups, the 
cells received the following treatments for 24 or 48 hours: 10
-5 
M norepinephrine (NE, 
dissolved in PBS) (Sigma), 10nM 17-β-estradiol (E2, dissolved in DMSO) (Sigma), NE+ 
E2, NE+ E2 and Compound C (40 μM, dissolved in DMSO) (Sigma), NE+ E2 and 
Rapamycin (20 nM, dissolved in DMSO) (Sigma). The control groups received the equal 
volume of the solvents only. 
 
Cell viability assessment via trypan blue exclusion method  
Cell viability was measured in control groups and after 24 and 48 h treatment with different 
reagents. 1:1 volume of cell suspension in phosphate-buffered saline (PBS) and trypan blue 
solution (0.4% in PBS) was mixed, and the number of stained (live) and unstained (dead) 
cells were counted in a Neubauer chamber. Cell viability percentage was assessed by 
calculating the percentage of stained cells with trypan blue to the total number of stained and 
unstained cells by an experimenter who was blind to the identity of experimental groups. 
 
Protein quantification  
Protein quantification, followed by western blot analysis were performed at the end of the 
treatment periods of 24- 48 h. The cells were collected in the lysis buffer (5 mM Tris–HCl, 
150 mM NaCl, 1 mM ethylenediaminepentaacetic acid, 0.2 % Triton X-100, 1 µg/ml 
pepstatin, 1 µg/ml leupeptin, 1 mM Na3VO4, 0.5 mM phenylmethylsulfonyl fluoride, 50 mM 
NaF) on ice for 30 min with a 1 min vortex every 10 min. The lysed cells were centrifuged at 
100,000×g for 30 min and supernatant was collected for further analysis. 
The total protein in each sample was calculated, using an EZQ assay following the approved 
protocol (BioRad, Hercules, CA, USA) as it was described before (Domise et al., 2016). 
Briefly, 10 μL of sample, 25 μL of four times sample buffer (100% glycerol, 1M Tris/HCl pH 
6.8, SDS, beta‐mercaptoethanol, H2O) and 65 μL H2O were mixed. A quantity of 10 μL of 
this solution was added to 90 μL of H2O, thereafter 1 μL of each sample and the standard 
solution (serial dilutions of ovalbumin) were loaded on to the assay paper in triplicate each in 
96‐well plates and absorbance was measured, using an Image Master VDS‐CL (Amersham 
Biosciences) and quantified by CareStream molecular imaging software. 
 














For western blot analysis, 30 μg of sample in sample buffer was loaded to each well of 
AnykD
™
 TGX Stain‐free gel (Bio‐Rad; 569033) followed by applying the current to the gel 
for 20 min (100V, 300 mA). After standard SDS‐PAGE separation based on their molecular 
weights, the proteins were transferred onto Polyvinylidene Difluoride (PVDF) membrane at 
100 V for 30 min. Subsequently the membranes were blocked in solution of 5% non‐fat dry 
milk in Tris‐buffered saline (TBS) containing 0.1% Tween 20 (pH 7.6), thereafter were 
incubated overnight at 4 °C with primary antibodies of: rabbit p‐tau (Ser396) (polyclonal; 
1:250), rabbit p‐tau (Ser262) (polyclonal; 1:250), mouse p‐tau (Ser202/Thr205) (polyclonal; 
1:250), mouse tau (monoclonal; 1:250), p‐GSK‐3β (Ser9) (polyclonal, 1:500), GSK‐3β 
(polyclonal; 1:500), p‐PP2A‐Cα/β (monoclonal; 1:500), PP2A‐Aα (polyclonal; 1:500) and 
mouse β-actin  (monoclonal; 1:500). On the following day, membranes were incubated for 
1 h at room temperature with the HRP secondary antibodies (Donkey anti‐ mouse, 1:3000; 
Donkey anti‐rabbit, 1:3000, Donkey anti‐goat, 1:10,000). The blots were subsequently 
developed using an ECL and the chemiluminescence signal detection was performed using 
Fuji LAS4000 imager, quantified by CareStream molecular imaging software, and was 
corrected by β-actin levels. 
 
Immunofluorescent staining 
Culture slides were fixed with 4% paraformaldehyde (Sigma, USA). The cells were 
permeablized using  0.2% Triton X-100 in TBS, and non-specific binding was blocked with 
5% non‐fat dry milk in TBS containing 0.1% Tween 20 (pH 7.6) for 1 h at room temperature. 
Immunofluorescence staining was undertaken by incubating the slides with rabbit anti p-tau 
(Ser
396
, 1:250), or mouse anti tau (1:250) for 18 h at 4
o
 C to detect tau and p-tau (Ser
396
) 
immunofluorescence staining. Subsequently, the slides were incubated for 1 h at room 
temperature with the secondary antibodies of Donkey anti-rabbit (Alexa Flour _488, 1:500) 
and Donkey anti-mouse (CY3, 1:500). The fluorescent staining was visualized using a Leica 




All of the data in this study were analysed using IBM SPSS Statistics version of SPSS 














differences between the means of the groups followed by post hoc Tukey's. Significance was 




SH-SY5Y cell differentiation to mature neurons following 7 days of RA treatment in a 
FBS free DMEM/F12 culture medium 
To study the effect of norepinephrine (NE) and 17-β-estradiol (E2) on tau phosphorylation 
(p-tau) at Ser
396
, in mature neurons, SH-SY5Y neuroblastoma cells were differentiated to 
mature neurons. To do so, the cells were treated with Fetal Bovine Serum (FBS) free medium 
supplemented with 10 µM of Retinoic Acid (RA). The results showed that the differentiation 
began in the second day of treatment (Fig. 1a) and continued up to seven days, by showing 
the elongation of neuronal-like processes extending from the cells (Fig. 1b and c). Immuno-
fluorescent staining with MAP2 as the specific marker for mature neurons, confirmed the 
differentiation of SH-SY5Y cells to mature neurons at day 7 (Fig. 1d). 
 
Viability of differentiated SH-SY5Y cells following 24 and 48 hours of treatment with 
NE and E2 
To evaluate the effect of NE and E2 individual treatment and in combination in the presence 
and absence of Compound C and Rapamycin on cell survival, trypan blue exclusion assay 
was performed to calculate the percentage of cell survival. Our results showed no effect of 
our treatment on cell survival. That was presented by the percentage of trypan blue positive 
cells (stained) in the total population of cells (stained and unstained) after 24 and 48 h of 
treatment with NE and E2, the combination of both and with and without Compound C and 
Rapamycin compare to control group (Fig. 2).   
 












Considering the demonstrated role of stress-related hormones on p-tau and the effect of E2 on 
regulating stress response, we examined the effect of NE/ E2 treatment separately and in 
































affected by the other tau kinases but not AMPK. Compare to control groups, western blotting 













) to tau ratio, in 
groups that separately treated with NE or E2 (One Way ANOVA, *p < 0.01) (Fig. 3). Also 
Co-treatment with NE and E2 significantly increased p-tau (Ser
396
) and p-tau (Ser
262
) (One 




) compared with 
control group, however the level of increase was less than treatment with E2 or NE 
individually (the difference was not significant) (Fig. 3). Beta-actin levels remained the same 
across all lanes, confirming the equal loading of proteins in all wells. 
 
Effect of Compound C and Rapamycin individually and in combination on p-tau 
(Ser
396
) and p-tau (Ser
262
) following NE and E2 co-treatment 
Previous studies suggested a role for AMPK/mTOR axis in tau pathology and AD 
development (Caccamo et al., 2013; Domise et al., 2016).  In view of these results, along with 
the reports on the positive impact of E2 and NE on AMPK and mTOR activation, we 





) in the presence of NE and E2. Blocking AMPK by Compound C 




 (One Way ANOVA, vs control group, *p < 0.01) (Fig. 4), 




) to tau, while the 





) in presence of NE and E2, however, co-treatment with 




) after 24 (Fig. 
4A) and 48 h of treatment (Fig. 4B) (One Way ANOVA, vs NE+E2 group **p < 0.01). 
Immunofluorescent (IF) staining results showed an increase in p-tau (Ser
396
) (Fig. 5. e, f, g, h) 
in NE+E2 treated compared with control group (Fig. 5 a, b, c, d), while the staining of tau 
(Ser
396
) decreased subsequent to exposing the cells to Compound C (40 μM) (Fig. 5. i, j, k, l), 
supporting our western blot findings.  
 
Effect of NE and E2 individually and in combination on p-AMPK (Thr
172
) in the 
presence and absence of Compound C and Rapamycin  
With the respect to the suggested kinase role for p-AMPK (Domise et al., 2016) and to 














phosphorylation, the activity level of AMPK was assessed in NE and E2 treated with and 
without Compound C and Rapamycin. Our results revealed a significant AMPK activity (p-
AMPK/AMPK ratio) in the presence of NE and E2 (One Way ANOVA, vs control group, *p 
< 0.01) compared with control group. Our finding showed that compound C blocked this 
activation (Fig. 6) while treatment of the cells with Rapamycin had no effect on the enhanced 
AMPK activity in the presence of NE and E2 (Fig. 6). Our results from immunofluorescent 
staining confirmed the higher level of p-AMPK in the presence of NE and E2 after 24 h (Fig. 
7 d, e, f) than control group (Fig. 7 a, b, c). Compound C treatment reduced p-AMPK (Fig 7 
g, h, i), however AMPK remained highly activated in the presence of Rapamycin in NE+ E2 
treated groups (Fig 7 j, k, l).  
PP2A activity in NE and E2 treated groups in the presence and absence of Compound C 
and Rapamycin  
Recent findings indicate a major role for protein phosphatase 2A (PP2A) down-regulation in 
tau hyperphosphorylation in AD (Qian et al., 2010; Sontag and Sontag, 2014). There is also a 
suggested role for NE and mTOR in modulating PP2A activity (Peterson et al., 1999; Pullar 
et al., 2003). To investigate the role of PP2A in tau hyperphosphorylation under NE and E2 
treatment, PP2A activity (p-PP2A/PP2A ratio, normalized by β-actin intensities) has been 
evaluated. The results showed that PP2A activity remained at same levels in all treated and 
control groups with NE and E2 (β-actin levels remained the same across all lanes). The level 
of PP2A activity also did not show any significant change after blocking the AMPK and 
mTOR pathways with Compound C and Rapamycin, respectively (Fig 8A). 
 
GSK-3β activity in NE and E2 treated groups in the presence and absence of Compound 
C and Rapamycin 
As reported previously, AMPK activation can increase Glycogen Synthase Kinase-3β (GSK-
3β) activation through reducing its phosphorylation at Ser
9
 (Horike et al., 2008). Because 
GSK-3β is one of the main kinases responsible for tau phosphorylation in AD brains (Hanger 
and Noble, 2011), we investigated its GSK-3β in tau hyperphosphorylation that we observed 
in differentiated SH-SY5Y cells after 24 and 4h h treatment with NE/E2. The results showed 
no significant difference between treated groups compared with control in GSK-3β activity 
(p- GSK-3β/ GSK-3β). The β-actin levels remained the same across all lanes (Fig. 8B) and p- 
























We previously demonstrated a specific role for adenosine monophosphate kinase protein 
kinase (AMPK) in phosphorylating tau, a main hallmark for Alzheimer’s disease (AD) and 
other tauopathies in neurons under hypoxic stress (Majd et al., 2017). It is believed that 
stimulation of hypothalamic-pituitary-adrenal (HPA) stress axis, leading to overproduction of 
cortisol and norepinephrine (NE), may participate in tau phosphorylation (p-tau) and beta 
amyloid production (Feng et al., 2005; Mravec et al., 2014; Rissman et al., 2007; 
Sotiropoulos and Sousa, 2016). From two main hallmarks of AD, p-tau seems to be an 
essential element in developing the pathology under stress (Lopes et al., 2016). The cellular 
mechanisms, linking NE release to p-tau, are not fully understood. In current study, we used 
an in vitro model of differentiated human neuroblastoma SH-SY5Y cells. The full 
differentiation of cell was proven by their positive staining with microtubule associated 
protein 2 (MAP2) in our study. For these cells, the presence of adrenergic receptors have 
been documented previously (Kazmi and Mishra, 1989).  Specifically, it was demonstrated 
that differentiated SH-SY5Y cells to mature neurons under retinoic acid treatment (the same 
as our protocol), express NE receptors, NE transporter (NET) and the vesicular monoamine 
transporter (VMAT), some of the characteristic of adrenergic neurons (Kovalevich and 
Langford, 2013). 




), two AMPK 




, have been proven as 
two residues of tau that are sensitive to kinase activity of AMPK, the main energy regulator 
of cells under stress (Gu et al., 2013; Thornton et al., 2011). This finding is consistence with 





under stressful conditions such as hypoxia, hypothermia, and 














It was suggested that stress stimulated release of central NE (Nisenbaum et al., 1991).  Our 
finding showed the positive effect of NE on tau phosphorylation. This finding suggests that 
NE, an important component of stress response could play a critical role in in tauopathy. In 
accordance with our results, Braak et al. demonstrated an extensive level of tau neuropathy, 
which happened at the very first stages of AD in locus coeruleus (LC), the main NE source of 
brain (Braak et al., 2011). Many other experimental evidence proposed a substantial role for 
NE receptors, especially β1 and β2 in tau hyperphosphorylation, through activating protein 
kinase A (PKA) and c-Jun N-terminal kinase (JNK) cascade (Wang et al., 2013). 
Norepinephrine also increases the expression of serine-threonine kinases, some of them with 
tau kinase activity (Chenal and Pellerin, 2007; Hutchinson et al., 2005). The role of stress in 
tauopathy was further confirmed when a substantial elevation in p-tau was reported through 
exposing animals to long period of restraining stress, a stimulatory model to anxiety and 
social stress in humans (Rissman et al., 2012). 
 One of the examples of the stressful situation in humans is the transition phase to 
menopause, and the menopause itself in women. The controversy around the impact of this 
transition on tau phosphorylation and AD development is remained to be clear. While our 
findings showed the positive impact of each 17-β-estradiol (E2) and NE on p-tau, 
combination of both generated a milder effect. It was previously reported that NE effect 
could be modulated by estradiol (Conrad et al., 2004; Herbison et al., 2000; Shansky et al., 
2004). The effect of estradiol on memory by itself, as the main female sex hormone is still 
controversial. A suggested role for estradiol in memory improvement through binding to 
neurotrophin receptors, activation of phosphatidylinositol3-kinase (PI3K) and mTOR 
pathway followed by protein synthesis (Luine, 2014) was suggested before. In opposite, a 
large human study showed that giving estradiol to women at late menopause actually 
increased the risk of dementia (Luine, 2008). Some studies reported that estradiol improved 
cognitive performance in adult and middle-aged ovariectomized rats and mice via activation 
of estrogen alpha (ERα) and beta (ERβ) receptors (Rodgers et al., 2010; Talboom et al., 
2008), while some others showed no significant effect of hormone therapy in reducing the 
risk of AD (Imtiaz et al., 2017; Ohm et al., 2012). While experimental situation could be the 
reason for this conflict, the level of estrogen receptors’ involvement during different periods 
of time and in different conditions could be an explanation.  
A recent study demonstrated that activation of ERα by estradiol positively regulated the p-tau 
(Xiong et al., 2015). Differentiated SH-SY5Y cells contains a substantial level of estradiol 


















after 24 and 48 h of treatment. These results could 
be explained by the previous finding, showing the existence of two ERα and ERβ receptors 
for estradiol, while ERα positively, whereas ERβ negatively, regulated p-tau (Xiong et al., 
2015). Other evidence suggest the preference of E2 in acting though ERα but not ERβ in a 
variety of situations (Wang et al., 2004). Interestingly, the proposed neuroprotection effect of 
estradiol through its anti-inflammatory effect is believed to be mediated by ERα (Vegeto et 
al., 2003) while the impact of this activation on p-tau at the same time could limit its positive 
effect. This could clarify the contradiction of the findings on protective effects of estradiol in 
different studies. Our findings showed that tau hyperphosphorylation was less prominent 
when we combined E2 with NE. That could be explained by the modulatory role of E2 on NE 
function (Manly et al., 2000), or more probably, the effect of NE in reducing the nuclear 
estrogen receptors which has previously reported (Montemayor et al., 1990). 
Tau phosphorylation in our study remained significantly higher in NE+E2 treated groups 
compared with control group. Apart from modulatory effect of E2 on NE (Conrad et al., 





) in presence of NE and E2, could be explained by the others’ reports. 
Previous evidence showed a common stimulatory effect of both NE and E2 on AMPK 
pathway (Chen et al., 2014; Hutchinson et al., 2005; Lipovka et al., 2015; Yin et al., 2003). 




 two AMPK insensitive sites of tau (Domise et al., 2016) 
was not affected by NE and E2 in the current study. This supports our hypothesis, suggesting 
that tau hyperphosphorylation effect of NE and E2 is mediated through AMPK. Our current 





) in differentiated SH-SY5Y cells following NE and E2 co-exposure. AMPK is one of 
the main intracellular pathways that activates under different stress conditions (Batandier et 
al., 2014). AMPK family of proteins act as one of the main tau kinases phosphorylating tau at 




(Gu et al., 2013; Thornton et al., 2011). 
Demonstrating AMPK activation by E2 and NE in this study is in compliance with previous 
reports, proposing that activation of AMPK by E2 enhances AMPK α-catalytic subunit 
phosphorylation (Rogers et al., 2009). Further studies revealed that the AMPK activation via 
E2 is mediated through estrogen receptor α/β (Lipovka et al., 2015). Adrenergic signaling 
pathway also leads to increase in AMPK activation through AMPK α1 subunit 
phosphorylation (Mulligan et al., 2007), with a specific role for β-adrenergic receptor 
activation by NE (Hutchinson et al., 2005). It is not still clear whether AMPK activation 














inhibitor of AMPK, Compound C, in the presence of NE and E2, we observed a significant 
reduction in p-tau that was occurred before applying Compound C. This finding suggests that 
the hyperphosphorylation of tau in our study was mainly mediated through AMPK activation.  
Along with AMPK, mTOR is the other element in regulating cellular response to stress as 
downstream target of AMPK. It was shown that upregulation of mTOR signaling pathway 
plays an important role in major pathological processes of AD, including beta Amyloid 
accumulation and tau phosphorylation (Cai et al., 2015; Xu et al., 2012). mTOR activation 
itself is modulated by other factors including NE and E2. It is reported that both NE and E2 
increase activation of mTOR (Luine, 2014; Yu and Henske, 2006), which raises the 
possibility of mTOR involvement in their effects on tau phosphorylation. Our results showed 




) elevation due to 
NE/ E2 treatment. Co-treatment of CC and Rapamycin, in order to block the possible 
activated mTOR due to AMPK inhibition, did not make any change in the effect of AMPK 




). This finding suggests that NE and E2 effect 
on tau hyperphosphrylation is mediated through AMPK activation in this study. 
Serin
396
 could also be phosphorylated by Glycogen Synthase Kinase-3β (GSK-3β), and 
dephosphorylated by Protein Phosphatase 2A (PP2A), two main tau kinase and phosphatase. 
Human studies showed the enhanced activation of GSK-3β and declined activity of PP2A, in 
AD brains (Ferrer et al., 2002; Rudrabhatla and Pant, 2011). To determine the involvement of 




) increase due to NE/E2 treatment, the activity 
of GSK-3β and PP2A were examined in our study. The current findings showed no 
significant change in activity levels of these enzymes, suggesting the AMPK-mediated effect 
of NE/E2 co-treatment as the possible mechanism for tau hyperphosphorylation. It is also 
important to note that in parallel with this cascade, the interaction between NE and E2 could 









, one of the main hallmarks of AD. This 
hyperphosphorylation in mainly mediated via AMPK activation, with no significant 
involvement of mTOR, GSK-3β and PP2A pathways. Combining these findings, with the 














strategies such as hormone therapy to prevent AD, must be taken in action with extra cautious 
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Figure 1. SH-SY5Y differentiation to mature neurons. Differentiation of SH-SY5Y cells 
began at the second day of treatment with 10 µM of Retinoic acid (RA) in Fetal Bovine 
Serum (FBS) free DMEM/F12 culture medium (Fig. 1a). The elongation of the cellular 
processes continued for 7 days (Fig. 1b and c), and the immuno-fluorescent staining with 
specific marker for the mature neurons, MAP2, confirmed the fully differentiation of the cells 
to mature neurons after 7 days of differentiation (Fig. 1d). Scale bars, 25 μm. 
 
Figure 2. The effect of 24 and 48 h treatment with norepinephrine (NE) (10
-5
 M) and 17-β-
estradiol (E2) (10 nM) in the presence and absence of Compound C (CC; 40 μM), Rapamycin 
(Rap; 20 nM), and a combination of both on cell viability using trypan blue exclusion 
method. The percentage of cell death did not show any significant difference between groups. 
Error bars depict the SD. 
Figure 3. Norepinephrine and 17-β-estradiol (E2) individually and in combination increase 













) and tau protein in control, norepinephrine (NE), 17-β-estradiol (E2) 




) to tau ratio after 
normalizing data with β-actin intensities showed significant increase in tau phosphorylation 
at Ser
396
 in treated groups with 10
-5 
M of NE, 10 nM of E2, and NE+ E2 compared with 




) showed the 




) increase in NE+ E2 
group was less than individual treatment with each NE or E2, in both 24 and 48 h of 
treatment, however the difference between them was not significant. Error bars depict the SD. 
All values are expressed as percent change relative to control group and were corrected by 
























) and tau protein along with the quantification assay of p-tau 
(Ser
396
)/ tau and p-tau (Ser
262
)/ tau after 24 h (A) and 48 h (B) treatment of NE+E2 groups 
with Compound C (CC; 40 μM), Rapamycin (Rap; 20 nM), and the combination of both.  
Significant increase in p-tau (Ser
396
)/ tau and p-tau (Ser
262
)/ tau were observed in NE+E2 
group compared with control group (One Way ANOVA, vs control group, *p < 0.01). The 
results showed the significant decrease in p-tau (Ser
396
)/ tau and p-tau (Ser
262
)/ tau following 
24 and 48 h treatment with Compound C, and the combination of Compound C and 
Rapamycin (One Way ANOVA, vs NE+E2 treated group, **p < 0.01) but not Rapamycin 
alone, compared with NE+E2 treated group (Fig. 4). Error bars depict the SD. All values are 
expressed as percent change relative to control group and were corrected by the β-actin level.  
 
Figure 5. Immunofluorescent (IF) staining showed no significant p-tau (Ser
396
) elevation in 
NE+E2 group treated with Compound C. Differentiated SH-SY5Y cells showed an increase 
in their p-tau (Ser
396
) levels (Green) following 48 hours treatment with NE+E2 (Fig. 5. e, f, g, 
h) compared with control group (Fig. 5 a, b, c, d ). Compound C (40 μM) treatment decreased 
tau phosphorylation at Ser
396
 (Fig. 5 I, j, k, l). The tau showed the same level of staining in all 
groups (Red). Scale bars (a-d:  10 μm; e-l: 25 μm) 
 
Figure 6. Adenosine monophosphate protein kinase protein (AMPK) activity increased under 
NE and E2 treatment. A) Western blot data of p-AMPK (Thr
172
) and total AMPK in 
norepinephrine (NE), 17-β-estradiol (E2), NE+ E2, NE+ E2 with 40 µM Compound C (CC), 
NE+ E2 with 20 nM Rapamycin (Rap) and 40 µM Compound C, and NE+ E2 with 20 nM 
Rapamycin only, showed the substantial increase in NE+ E2 group after 24 and 4 h. The 
increased activity was blocked with Compound C, but not Rapamycin. B) Quantification 
analysis revealed a significant increase in AMPK activity (p-AMPK/ AMPK ratio) in NE+ 
E2 treated groups compared with control group. The enhanced activity was diapered after 
Compound C treatment. Error bars depict the SD. All values are expressed as percent change 
relative to control group and were corrected by the β-actin level.  
Figure 7. Immunofluorescent (IF) imagining showed a substantial increase in Adenosine 
















24 h cell treatment with norepinephrine (NE) and 17-β-estradiol (E2) (d, e, f) compared with 
control group (a, b, c). Compound C (CC) reduced p-AMPK (g, h, i) in NE+E2 treated 
groups, while AMPK remained highly phosphorylated in the presence of Rapamycin (Rap) in 
NE+E2 group (j, k, l). Scale bars, 10 μm. 
Figure 8. A) Protein Phosphatase 2A (PP2A) activity remained unchanged in all groups. 
Western blot results of p-PP2A and total PP2A in norepinephrine (NE), 17-β-estradiol (E2), 
NE+ E2, NE+ E2 with 40 µM Compound C (CC), NE+ E2 with 20 nM Rapamycin (Rap) and 
40 µM Compound C, and NE+ E2 with 20 nM Rapamycin only, showed the same intensity in 
the bands in all lanes. Quantification analysis revealed no significant difference in p-PP2A/ 
PP2A in all treated groups after 24 and 48 h compared with control group. B) Glycogen 
Synthase Kinase-3β (GSK-3β) activity in norepinephrine (NE) and 17-β-estradiol (E2) 
treated groups in the presence and absence of Compound C (CC) and Rapamycin (Rap) 
remained unchanged. Western blot results of p-GSK-3β and total GSK-3β in all tread groups 
(norepinephrine (NE), 17-β-estradiol (E2), NE+ E2, NE+ E2 with 40 µM Compound C, NE+ 
E2 with 20 nM Rapamycin and 40 µM Compound C, and NE+ E2 with 20 nM Rapamycin 
only) revealed the same intensities for p-GSK-3β and total GSK-3β bands in all groups. 
Quantification analysis of western blot results showed no significant difference in p-PP2A/ 
PP2A between treated groups after 24 and 48 h compared with control group. Error bars 
depict the SD. All values are expressed as percent change relative to control group and were 
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1- NE and E2 treatment separately, and in combination increase tau phosphorylation at Ser396 and 
Ser262 (AMPK- sensitive residues) but not Ser202/Thr205 (AMPK- insensitive residues). 
2- Compound C inhibits AMPK activity and blocks p-tau (Ser396, 262) elevation due to NE and E2 
treatment. 
3- Rapamycin (m-TOR inhibitor) has no effect on NE+ E2 dependent p-tau elevation at (Ser396, 262). 
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